[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Core Insights - Roche announced topline results from pivotal phase IIb ALIENTO and phase III ARNASA trials for astegolimab in chronic obstructive pulmonary disease (COPD) patients [1][2][3] Study Results - The phase IIb ALIENTO study met its primary endpoint, showing a statistically significant 15.4% reduction in the annualized exacerbation rate (AER) at 52 weeks with astegolimab administered every two weeks [2][6] - The phase III ARNASA study did not meet its primary endpoint, demonstrating a numerical 14.5% reduction in AER at 52 weeks with the same dosing regimen [2][6] - Both studies showed consistent results across secondary endpoints, with total exacerbations lower than anticipated [2][6] Safety Profile - The safety profile of astegolimab was consistent with previously reported data, with no new safety signals identified [2][6] Future Steps - Roche plans to discuss the data with regulatory authorities to evaluate next steps for astegolimab [3][6] - Detailed results from both studies will be shared at an upcoming medical meeting [3][6] About Astegolimab - Astegolimab is a fully human anti-ST2 monoclonal antibody designed to block IL-33 signaling, evaluated in a broad COPD population including former and current smokers [4][6]